Evan Wang
Stock Analyst at Guggenheim
(0.20)
# 4,688
Out of 5,182 analysts
6
Total ratings
25%
Success rate
-17.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Reiterates: Neutral | n/a | $54.77 | - | 3 | Dec 12, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $1.38 | +552.17% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $5.53 | +207.41% | 1 | Mar 22, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $47.14 | - | 1 | Apr 26, 2023 |
Spruce Biosciences
Dec 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $54.77
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $1.38
Upside: +552.17%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $5.53
Upside: +207.41%
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $47.14
Upside: -